Treating pain has long been a challenge. Over-the-counter treatments often don’t do enough, while opioids block pain signals but can be extremely addictive. Vertex broke those barriers with Journavx, ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Vertex Pharmaceuticals’ CRISPR-based therapy made history as ...

Vertex Pharmaceuticals (VRTX) shares saw mild movement today, with the stock ticking slightly higher over the past week. Investors seem to be watching recent performance rather than reacting to fresh ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

MANILA, Philippines — Union Bank of the Philippines and state-run pension fund Social Security System (SSS) have unveiled a new Visa debit card that doubles as a valid identification card. This is ...

The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...